Physician profile
Rahul Sinha
NPI 1629332606
$7,572.15
in general payments reported to CMS, 2019-2025
16 companies · $756 in 2025
The $756 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,109 · 2020: $644 · 2021: $560 · 2022: $707 · 2023: $847 · 2024: $2,950 · 2025: $756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,244 · Travel and Lodging: $1,277 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,243.94 |
| Travel and Lodging | $1,276.63 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,731.53 | 2019-2025 | Watchman Access System, Watchman Flx, General - Structural Heart |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,118.43 | 2019-2025 | Lifevest |
| Abbott Laboratories | $555.71 | 2022-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Astrazeneca Pharmaceuticals LP | $433.90 | 2019-2022 | |
| Amgen INC. | $361.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $253.16 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $205.49 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| United Therapeutics Corporation | $168.36 | 2022 | |
| Medtronic, INC. | $165.94 | 2025 | Corevalve Evolut R |
| E.R. Squibb & Sons, L.L.C. | $135.42 | 2022-2025 | Camzyos |
| Novartis Pharmaceuticals Corporation | $123.95 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $119.52 | 2023-2024 | Verquvo |
| Abiomed | $67.38 | 2024 | Impella |
| Pfizer INC. | $61.55 | 2020 | |
| Scpharmaceuticals INC. | $60.59 | 2023-2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $9.63 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahul Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.